Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	53 people with early breast cancer receiving adjuvant fluorouracil plus epirubicin plus cyclophosphamide (FEC) or cyclophosphamide plus methotrexate plus fluorouracil (CMF)	Sedation 86%–92% with lorazepam (depending on what chemotherapy regimen given) 8%–10% with placebo (depending on what chemotherapy regimen given) Absolute results not reported	Reported as significant difference between groups P value not reported	Effect size not calculated	placebo
RCT	53 people with early breast cancer receiving adjuvant fluorouracil plus epirubicin plus cyclophosphamide (FEC) or cyclophosphamide plus methotrexate plus fluorouracil (CMF)	Amnesia 48%–50% with lorazepam (depending on what chemotherapy regimen given) 0% with placebo Absolute results not reported	P value and statistical analysis between groups not reported